Thanks to the unique organization of sarcoma care in France, the national database, the dynamism of the French Sarcoma Group and the capacity of their key opinion leaders to establish collaborations with pharma, the CONDOR partners are the most advanced in the field of sarcoma immunotherapy with the largest portfolio of immunotherapy trials worldwide. In this regard, CONDOR is unique by its capacity to leverage all the biological resources, and the patient recruitment potential needed to deliver its outputs.
We will develop 4 main deliverables:
A sarcoma immune atlas
(Characterization of sarcoma microenvironment)
plasma based signature
Early phase trials
with new targets
This project has benefited from a government grant managed by the Agence Nationale de la Recherche
under the 3rd AIP, integrated into France 2030
with the reference ANR-21-RHUS-0010.